3559 results for «267»
3559 results
DCB after REC-CAGEFREE 1 - Vulnerable plaque PCI after PREVENT
21 May 2025 – From EuroPCR 2025
Reflect on the impact of recent trials REC-CAGEFREE 1 and PREVENT on the use of drug-coated balloons (DCB) and preventive PCI for vulnerable plaque. This session includes case discussions highlighting DCB applications and insights from cutting-edge clinical studies.
Multi-modality assessment of coronary disease
21 May 2025 – From EuroPCR 2025
This session offers comprehensive multi-modality assessment of coronary disease, integrating advanced imaging and functional testing. Topics include diagnostic yield of OCT and cardiac MRI for MINOCA, transitioning coronary plaque vulnerability assessment from invasive to non-invasive methods, relationships between QFR and IVUS post-PCI in complex lesions, combined...
ACS with normal coronary arteries: angiography done, job done?
21 May 2025 – From EuroPCR 2025
Understand the clinical significance of MINOCA and learn diagnostic strategies integrating invasive and non-invasive tests to identify underlying etiologies. This session provides therapeutic insights tailored to specific MINOCA endotypes through illustrative cases.
New tools for left main treatment
21 May 2025 – From EuroPCR 2025
Examine new tools and strategies tailored for left main coronary artery treatment. This session covers real-world data on intracoronary imaging guidance, post-PCI FFR assessment following provisional T stenting, safety and efficacy of intravascular lithotripsy for calcified left main disease, drug-coated balloon (DCB) treatments for true bifurcation...
Optimising CTO outcomes by lesion selection
21 May 2025 – From EuroPCR 2025
Optimize chronic total occlusion (CTO) PCI outcomes through lesion selection strategies. This session reviews coronary calcium patterns via CT, target vessel considerations, distal vessel remodeling, imaging-guided versus conventional approaches, and complex lesion cases.
TAVI: contemporary practice
21 May 2025 – From EuroPCR 2025
Stay updated on contemporary TAVI practices with insights from the 2024 European TAVI PATHWAY Registry. This session addresses comprehensive risk stratification in moderate aortic stenosis, safety and efficacy of repeat TAVI procedures, comparative outcomes of explant versus redo-TAVI after valve failure, and long-term neurological outcomes following...
Hotline TAVI 2: outcomes with new and established devices
21 May 2025 – From EuroPCR 2025
Review outcomes of new and established TAVI devices through pooled analyses and multicenter studies. Topics include comparisons of balloon-expandable valves, intra- versus supra-annular self-expanding valves, and insights from the ACURATE IDE and ACURATE prime studies.
Intracoronary imaging for complex PCI: a must!
21 May 2025 – From EuroPCR 2025
Recognize the indispensable role of intracoronary imaging in managing complex PCI cases. This session explores the evolution of multivessel NSTEMI treatment using DES, BRS, DCB, and imaging, challenges with recurrent in-stent restenosis across multiple stent layers, innovative imaging solutions for complex lesions, and diagnostic approaches to...
Management of stent-related complications
21 May 2025 – From EuroPCR 2025
This session addresses the management of stent-related complications through a series of dramatic clinical cases. Learn methodical approaches to routine and crisis scenarios including primary PCI complications, failure to stent, and unexpected challenges encountered during interventions, highlighting practical bailout techniques and decision-making frameworks.
How to select appropriate cardiovascular intervention for a patient with tricuspid regurgitation?
21 May 2025 – From EuroPCR 2025
Learn how to select appropriate cardiovascular interventions for tricuspid regurgitation patients by considering comorbidities, anatomical factors influencing procedural success, and imaging criteria for device selection. The session includes patient vignettes to illustrate decision-making pathways.
DCB in de novo lesions: new valid option?
20 May 2025 – From EuroPCR 2025
Explore the emerging role of drug-coated balloons (DCB) in treating de novo coronary lesions. This session discusses complexity management, comparisons with drug-eluting stents (DES), and the potential of DCBs as valuable alternatives, especially in high bleeding risk patients.
Myval Octapro THV - Optimise patient outcomes with novel design, data and daily clinical practice
21 May 2025 – From EuroPCR 2025
This session presents the latest updates on the novel Myval Octapro transcatheter heart valve (THV), based on one year of real-world clinical experience. Experts share practical tips and clinical cases that highlight how this innovative device can improve TAVI patient outcomes. The session also addresses imaging and...
Clinical outcomes of left main PCI
21 May 2025 – From EuroPCR 2025
This session reviews clinical outcomes of left main PCI in various contexts including ACS, complex lesion risk stratification with BCIS-CHIP score, and spontaneous coronary artery dissection. It also compares double-stent techniques and examines five-year results to guide clinical decision-making.
High bleeding risk and clinical outcomes in East Asian patients undergoing percutaneous coronary intervention: the PENDULUM registry
25 Feb 2021
The study aimed to evaluate the validity of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria for East Asian patients undergoing contemporary percutaneous coronary intervention (PCI) from the PENDULUM registry.
Authors :
SYNTAXES - Ten-year survival after coronary artery bypass grafting vs PCI: the SYNTAX Extended Survival study
03 Sep 2019
At the ESC Congress 2019 in Paris, Daniel Johannes presented the results of the SYNTAX Extended Survival study. Read the report by Mirvat Alasnag.
Author
Impact of intravascular imaging guidance on percutaneous coronary intervention of severely calcified lesions: The ECLIPSE trial
29 Mar 2025
Aaysha Cader provides her take on the ECLIPSE trial presented by Gregg W. Stone at ACC.25 in Chicago.
Author
BRIGHT-4 – Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial
07 Nov 2022
Nicola Ryan provides her take on the BRIGHT-4 study, which was presented during AHA 2022 in Chicago, & simultaneously published in the Lancet.
This study was a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 hours post PPCI was superior to unfractionated...
Author
Early intra-aortic balloon pump in heart failure complicated by cardiogenic shock: The Altshock-2 randomized clinical trial
31 Mar 2025
Mirvat Alasnag provides her take on the Altshock-2 randomized clinical trial which was presented by Alice Sacco at ACC.25 in Chicago.
Author
The JenaValve Trilogy™ heart valve system in high surgical risk patients with symptomatic, severe aortic regurgitation: The ALIGN AR Trial
25 Oct 2023
Nicola Ryan provides her take on the ALIGN AR trial which was presented by Vinod H. Thourani at TCT Congress 2023. The Align AR trial is a prospective single-arm investigation device exemption study assessing the safety and efficacy of the Trilogy transcatheter heart valve system in patients with...
Author
